Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.» Read More
Abbott Laboratories Wednesday said second-quarter earnings jumped 34 percent, beating its expectations, fueled by sizzling sales of its medical devices, Humira arthritis treatment and other drugs.
Which is the Street more worried about--declining stock prices, particularly for financials, or inflation? It's both, and this morning's action illustrates that concern. It's been a roller coaster of a morning, up on Wells Fargo, down on consumer inflation higher than expected.
Oil's move could be a key trend in Wednesday's markets, as traders watch more Fed testimony, a bunch of earnings reports and another helping of inflation data.
To give investors an edge in this volatile market environment, CNBC asked the experts for their best trades now.
At a time of market uncertainty, what can an investor count on? Knee replacements, for one thing. Bruce Nudell, UBS senior research analyst, takes that as his cue in picking some promising stocks.
The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.
The Dow rose Tuesday in another turbulent session after a pullback in oil prices eased worries about consumer and business spending. What's the "Word on the Street?"
Some traders are also turning bullish. John Mendelson of the Stanford Group issued a buy signal late in the day; traders tell me it was his 3rd buy signal in 5 years, and the prior two calls were very good.
Abbott Laboratories won U.S. approval to sell its drug-coated heart stent called Xience, the company said on Wednesday.
So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.
By anyone's reckoning, it was a rough week. Crude oil continued its relentless climb; banks and brokerages gave hints of more discouraging news; government data pointed to a weak economy; even strong companies like Nike, Oracle, and Research In Motion issued cautious guidance; and Federal Reserve policymakers, widely perceived as powerless to help, left interest rates unchanged. But all week, even through the worst of the market's sell-offs, CNBC guests offered
Where some stock-market investors see losses, Eric Schoenstein sees discounts. His four-star Jensen Portfolio is up an average of 4.7 percent per year over the last three years, and he's singled out some stocks he finds exceptionally promising and very reasonably priced.
FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."
Following are the week’s biggest winners and losers. Find out why shares of Abbott Labs and Starbucks popped while CBS and Dillard's dropped.
Two cardiologists write in "The New England Journal of Medicine" that Johnson and Johnson's first-of-its kind TV commercial for a heart stent is aimed at "millions of people who are ill-equipped to make judgments" about the device.
Following are the day’s biggest winners and losers. Find out why shares of Dell and Fluor popped while True Religion and Western Refining dropped
Stocks declined Tuesday as investors expressed their disappointment in Wal-Mart's outlook, HP's deal and a slew of other news. Surprising resilience in retail sales, excluding autos, helped curb losses. The Nasdaq eked out a gain, led by Yahoo.
Stocks declined Tuesday as investors juggled a mixed bag of news: Retail sales outside of the hard-hit auto sector showed suprising resilience, while a well-known analyst cut her outlook for big banks. Wal-Mart skidded after the discount giant posted decent results but issued a tepid outlook.
Too few influential doctors are telling the public if they have financial ties to the companies that make lifesaving drug-coated stents.
Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.